Sign in

GHDX on NASDAQ

Genomic Health

Genomics testing company based in Redwood City, founded in 20001

Genomic Health, Inc. is a company focusing on genetic research specifically in cancer detection, based out of Redwood City, California. The company was acquired by and merged with Exact Sciences Corporation in 2019.3 Its shares trade on NASDAQ under the symbol GHDX.1 Wikipedia text CC BY-SA 4.0

Price unavailable

Last updated Oct 21, 2026.

Overview

Aug 22, 2000Founded1

Compare with another stock.

  • TickerGHDX on NASDAQ1
  • IndustryServices-Medical Laboratories1
  • HeadquartersRedwood City1
  • Websitewww.genomichealth.com
  • Legal formDelaware corporation1
  • Business address301 Penobscot Drive, Redwood City, Ca 940635
  • Filer categoryLarge accelerated filer5
  • LEI549300QAH59D564PM5704
  • StatusActive4
  • LEI statusLapsed (not renewed)4
  • Registered addressC/O CORPORATION SERVICE COMPANY, 19808 Wilmington, United States4
  • Registered withDivision of Corporations, Department of State, 32721714

See how the biggest companies compare on our leaderboards

Genomic Health, Inc. is a company focusing on genetic research specifically in cancer detection, based out of Redwood City, California. The company was acquired by and merged with Exact Sciences Corporation in 2019.3

Corporate structure

Genomic Health is part of a group headed by Exact Sciences. 4 entities, 1 country on record. Switch between the flow chart and the network, and select any entity to see its details.

  • Exact Sciences Madison, Wisconsin, United States
    • Genomic Health Redwood City, California, United States
      • Oncotype DX Owned
    • Exact Sciences Laboratories, LLC Subsidiary · Delaware, United States
    • Exact Sciences Thrive, LLC Subsidiary · Delaware, United States

Built from parent and subsidiary links from GLEIF, the Global Legal Entity Identifier Foundation (CC0); subsidiaries listed in Exhibit 21 of annual reports filed with the SEC; subsidiaries, stakes and holdings from Wikidata (CC0). Each entity in the chart links to its source.

What it owns

What Genomic Health reports owning in its annual reports to the SEC: buildings, land and equipment, real estate and locations, investments, intangible assets and inventory, at the end of its latest fiscal year and a year before.

Property and equipment

ItemLatestA year beforeChange
Property and equipment, before depreciation$112.0M7 Dec 31, 2018$112.1M7 Dec 31, 2017−0.1%
Accumulated depreciation$72.5M7 Dec 31, 2018$65.7M7 Dec 31, 2017+10.3%
Property and equipment, net$39.5M7 Dec 31, 2018$46.4M7 Dec 31, 2017−14.9%

Investments

ItemLatestA year beforeChange
Cash and cash equivalents$61.6M7 Dec 31, 2018$45.5M7 Dec 31, 2017+35.4%
Marketable securities, current$148.1M7 Dec 31, 2018$84.1M7 Dec 31, 2017+76.2%
Marketable securities, non-current$4.1M7 Dec 31, 2018
Debt securities available for sale$151.4M7 Dec 31, 2018$84.1M7 Dec 31, 2017+80.1%

Stakes and holdings (Wikidata)

  • Oncotype DX

Things Wikidata records the company as owning, with the share when stated.1

The story

Genomic Health, Inc. was founded in 2000 by Randy Scott, who had previously founded and been CEO at Incyte. He formed the company after a close friend was diagnosed with cancer and had the idea for treatment based on the specific genome of their tumor.

By 2003 Genomic Health had developed Oncotype DX, a genomic assay that quantified the likelihood of breast cancer recurrence. This development took the company over three years and US$30,000,000 to complete and then had to convince skeptics at the time of the validity of genetic testing.

In July 2005 Genomic Health filed for an initial public offering to sell up to US$75,000,000 in common stock. Investors at the time already included Versant Ventures and Kleiner Perkins Caufield & Byers. On September 29, 2005 (2005-09-29) it was listed on the NASDAQ with the symbol GHDX with the initial share price of US$12 for 5016722 shares.

Genomic Health also started a subsidiary in 2010, Invitae, with the goal of aggregating multiple genetics tests. Invitae was spun off in 2012.

The company expanded with international headquarters in Geneva Switzerland and UK headquarters in London in 2011.

In July 2019, Exact Sciences announced that it was purchasing Genomic Health to increase the variety of medical tests they offer.

From Wikipedia’s article on Genomic Health, shared under CC BY-SA 4.0.6

Leadership

Who has led Genomic Health, and when. Pick a name to see everywhere that person has worked.

Chief executive

  1. Randal W. Scott2006–2012
  2. Kimberly J. Popovits2009–2019

Chair

  1. Randal W. Scott2006–2012

President

  1. Kimberly J. Popovits2006–2019

Chief financial officer

  1. G. Bradley Cole2006–2019
  2. Dean L. Schorno2011–2014

Chief operating officer

  1. Kimberly J. Popovits2006–2008
  2. G. Bradley Cole2009–2018
  3. Frederic Pla2018–2019
20052010201520202025
Board members and other officers (24)

Subsidiaries and ownership

Also owns

  • Oncotype DX

Parent company (GLEIF)

From Wikidata.1 Ownership links from GLEIF, the Global Legal Entity Identifier Foundation (CC0); each one cites its LEI record.

Timeline

  1. Jun 4, 2020Parent Directly consolidated by Exact Sciences4
  2. May 18, 2009New chief executive Kimberly J. Popovits becomes CEO8
  3. Dec 4, 2006New chief executive Randal W. Scott becomes CEO9
  4. Sep 29, 2005Went public Listed on NASDAQ1
  5. Aug 22, 2000Founded Founded1

SEC filer profile

How Genomic Health is registered with the Securities and Exchange Commission, from its EDGAR record and the cover page of its latest annual report.

  • Name on EDGARGENOMIC HEALTH INC2
  • CIK0001131324
  • Employer ID (EIN)77-05525942
  • Filer statusLarge accelerated filer2
  • Fiscal year endsDecember 312
  • Industry code (SIC)8071 Services-Medical Laboratories2
  • Business address301 Penobscot Drive, Redwood City, CA 940632
  • Phone650-556-93002
  • Shares outstanding37,587,598 as of Oct 28, 201938
  • Public float$1.0B as of Jun 30, 20187
  • On EDGAR sinceMar 21, 20022
  • Filings1,618 in all: 4 (1,108), 8-K (118), SC 13D/A (50), 3 (48), 10-Q (43), 425 (38), 4/A (30), SC 13G/A (30)2
    All 41 form types

    SC 13G (18), CORRESP (15), 10-K (14), DEF 14A (14), UPLOAD (14), EFFECT (7), 5 (6), S-1/A (6), ARS (5), S-3 (5), S-8 (5), S-8 POS (5), 424B3 (4), REGDEX (4), 144 (3), 8-K/A (3), SC 13D (3), 10-K/A (2), 424B5 (2), CT ORDER (2), DEFA14A (2), POS AM (2), REGDEX/A (2), 10-Q/A (1), 15-12G (1), 25-NSE (1), 3/A (1), 424B4 (1), 8-A12G (1), DEFM14A (1), NO ACT (1), S-1 (1), S-3/A (1)

  • Latest filingsAnnual report (10-K) Feb 28, 2019
    Quarterly report (10-Q) Oct 30, 2019
    Proxy statement (DEF 14A) Apr 25, 2019
    Latest 8-K (8-K) Nov 8, 2019

Sources

The numbers on this page point here. Each one links to the record it came from.

  1. 1
  2. 2
  3. 3
  4. 4
  5. 5
  6. 6
  7. 7
  8. 8
  9. 9
  10. 10
  11. 11
  12. 12
  13. 13
  14. 14
  15. 15
  16. 16
  17. 17
  18. 18
  19. 19
  20. 20
  21. 21
  22. 22
  23. 23
  24. 24
  25. 25
  26. 26
  27. 27
  28. 28
  29. 29
  30. 30
  31. 31
  32. 32
  33. 33
  34. 34
  35. 35
  36. 36
  37. 37
  38. 38